This is a first-in-human study to evaluate the feasibility, safety and preliminary antitumor
efficacy of autologous T cells genetically engineered with a CD19-specific chimeric antigen
receptor (CAR) and manufactured with a new process. CAR-T cells will be investigated in
combination with ibrutinib in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma
(SLL) and as single agent in diffuse large B-cell lymphoma (DLBCL) and in adult acute
lymphoblastic leukemia (ALL).